NGM·Healthcare·$115M·#137 / 520 in Healthcare
BDSX Biodesix, Inc.
60SPECULATIVE
CATEGORY BREAKDOWN
GROWTH39
QUALITY66
STABILITY53
VALUATION98
GOVERNANCE67
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+24.1%
39
> 50% strong
Gross Margin
Revenue retained after direct costs
81.1%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
10 months
29
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-2955.5%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.3x
98
< 3x strong
Rule of 40
Growth rate plus operating margin
-7
15
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
43.1%
100
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+38.0%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE BDSX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when BDSX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.